Reply Increases Its Presence in North America by Acquiring Enowa LLC and The Spur Group
REPLY [MTA, STAR: REY] strengthens its presence on the US market with the double acquisition of Enowa LLC (www.enowa.com) - a company specialized in consulting and development of solutions based on SAP technology - and The Spur Group (www.thespurgroup.com) - a leader in strategy consulting for marketing and sales.
Enowa LLC, headquartered in Philadelphia, is a leader in the fields of cloud design and value-added services on SAP technology and counts among its customers some of the main North American names in the space of Industrial Chemical, Consumer Services, Healthcare and Energy.
The Spur Group, based in Bellevue (Seattle), supports the main Tech Giants and global brands - including Cisco, Microsoft, Rockwell Automation, Qlik and VMWare - in defining go to market and positioning strategies combining skills in strategy, marketing, data analysis and operating models.
The investments in Enowa LLC and in The Spur Group, which together employ over 400 people, are part of Reply's international growth strategy, particularly in the United States, where Reply is already present in Atlanta, Chicago, Detroit, Kansas City, Seattle, and St. Louis.
The founders of Enowa LLC and The Spur Group with the role of "Partner Reply" will have the task of developing the activities of their respective companies within the Reply Group in North America.
"Enowa and The Spur Group - said Mario Rizzante, President of Reply - are both characterized by a great entrepreneurial spirit and constant attention to technological innovation. Thanks to the strong complementarity of their services with our current offer, we will create an optimal platform that will allow Reply to further develop its footprint in the United States, the most important world market for IT services."
Ali Sarraf, CEO of Enowa LLC commented: "We are very excited to be joining Reply’s network of companies as the leading SAP Consulting practice in North America. The strong interest in people, culture and customer focus that characterize Reply fit perfectly with our corporate culture. Together we will have the opportunity to bring new value to our customers."
"I’m thrilled to announce The Spur Group is joining Reply a company that shares the same focus on great experiences for its people and customers. - stated Randy Karr CEO of The Spur Group - We bring to Reply US network a set of unique capabilities, including strategic business consulting and go-to-market expertise. Reply has existing business in many different markets, current relationships with many of our targeted customers, standard processes and structures we can tap into, and a pool of capabilities we can now access. As a company, we are now stronger than we have ever been."
REPLY
Reply [MTA, STAR: REY, ISIN: IT0005282865] is specialized in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly focused companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
ENOWA LLC
Enowa is an SAP consulting company established in 2002 with a dedicated focus on business process and SAP consulting. With almost 20 years of experience, Enowa is an SAP Gold partner with recognized expertise in various industries executing domestic and global transformative projects. Enowa’s clients enjoy the expertise of certified, industry-leading experts, who understand their industry, business complexities and unique culture. Enowa’s consistency in delivering successful projects results in long-lasting, trusted relationships at all levels of our client’s organization. Please visit www.enowa.com for more information.
THE SPUR GROUP
The Spur Group is the leading provider of end-to-end go-to-market services. We turn customer, partner, and employee experiences into competitive advantages by helping our clients gain actionable insights, strengthen customer engagements, improve partner leverage, fuel execution excellence, and grow revenues faster. www.thespurgroup.com
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005608/en/
Contact information
REPLY
Media Contacts
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +442077306000
Investor Relation Contacts
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom